SLA had $438K in hand at Jan12, and were seeking $1.1M in debt...

SLA had $438K in hand at Jan12, and were seeking $1.1M in debt funding to get by. They did get $300k not sure they got the rest, but they did note Artlife JVed in Feb12 on the back of that deal - but no details. SibEx Limited is in theory still 85% owned by Solagran. Not sure of current arrangements with Salim Group, but NuvaPine A is available in Asia. Bioeffective A320 [Now re-labeled Taiga] & Siberian Red are all still quite widely available in Australia. Who knows what of Ropren sales in Russia. So there must have been some Sales Revenue and Operating Costs have been met by "somehow".

So many structural and funding questions.

The only positive US development/outcome I'm aware of was that at one stage the antioxidant Oracles, Brunswick Laboratories Massachusetts ratified BioA's antioxidant properties [at client cost].

On NuvaPine :- You can see Vagif on the hustings in this video (after initial TV panel's Segue). https://www.youtube.com/watch?v=WSj-YGpvA0Y

One would think the Opes & BPO related countersuits are well behind Vagif and Solagran - as he has done several of these "market promos" of late - and clamps on HC SLA discussions were lifted.